Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution
MT NewswiresMar 27 17:30 ET
Merrimack Receives $225M Milestone Payment From Ipsen
Seeking AlphaMar 27 16:36 ET
Merrimack Receives $225 Million Milestone Payment From Ipsen
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
BusinesswireMar 27 16:30 ET
Merrimack Pharmaceuticals Proposes Liquidation Plan
TipRanksMar 7 16:52 ET
Express News | Merrimack FY23 EPS $(0.08) Per Basic Share
Moomoo 24/7Mar 7 16:34 ET
Merrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December 31, 2023.
Business WireMar 7 16:30 ET
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen
Merrimack Pharmaceuticals (MACK) said Tuesday it is entitled to receive a $225 million milestone payment from Ipsen after the US Food and Drug Administration approved the supplemental new drug applica
MT NewswiresFeb 14 05:15 ET
Merrimack to Dissolve After FDA Nod Prompts $225 Million Payment
InvestingFeb 13 16:56 ET
Merrimack Pharmaceuticals to Get $225M Milestone Payment After FDA's Supplemental NDA Approval
By Sabela Ojea Merrimack Pharmaceuticals said it will receive a $225 million milestone payment from Ipsen after the U.S. Food and Drug Administration approved the supplemental new drug application fo
WSJFeb 13 16:49 ET
Merrimack Pharmaceuticals Weighs Dissolution Post FDA Approval
TipRanksFeb 13 16:34 ET
Express News | Merrimack Management Estimates That The Aggregate Amount Of The Liquidating Dividend Payable To Stockholders Will Be In The Range Of Between Approximately $14.65 And $15.35 Per Share
Moomoo 24/7Feb 13 16:25 ET
Express News | Merrimack Says Ipsen's FDA Approval Of Onivyde SNDA Triggers $225M Payment From Ipsen to Merrimack
Moomoo 24/7Feb 13 16:24 ET
Merrimack Spikes as Ipsen Wins FDA Label Expansion for Cancer Therapy
Seeking AlphaFeb 13 13:35 ET
Express News | BZ NOTE: Merrimack Pharmaceuticals, As Part Of Its Agreement With Ipsen For The Sale Of Its Oncology Assets Including ONIVYDE, Is Eligible To Receive Additional Payments With The Possibility Of Up To $450M Contingent Upon The Approval Of Potential New Ind
Moomoo 24/7Feb 13 13:31 ET
FDA Approves Irinotecan Liposome For First-line Treatment Of Metastatic Pancreatic Adenocarcinoma
On February 13, 2024, the Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatme
BenzingaFeb 13 13:19 ET
Merrimack Pharmaceuticals(MACK.US) Director Buys US$651.75K in Common Stocks
$Merrimack Pharmaceuticals(MACK.US)$ Director Andersen Eric purchased 49,550 shares of Common Stocks on Dec 26, 28, 2023 at an average price of $13.1535 for a total value of $651.75K. This transaction
moomoo NewsDec 28, 2023 16:18 ET
$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the sto
BenzingaDec 12, 2023 06:46 ET
Merrimack Pharmaceuticals(MACK.US) Director Buys US$1.3 Million in Common Stocks
$Merrimack Pharmaceuticals(MACK.US)$ Director Andersen Eric purchased 101.05K shares of Common Stocks on Dec 7, 2023 at an average price of $12.8498 for a total value of $1.3 million. This transaction
moomoo NewsDec 11, 2023 16:43 ET
Merrimack Pharmaceuticals(MACK.US) Director Buys US$3,750 in Common Stocks
$Merrimack Pharmaceuticals(MACK.US)$ Director Andersen Eric purchased 300 shares of Common Stocks on Nov 17, 2023 at an average price of $12.5 for a total value of $3,750. This transaction involves ot
moomoo NewsNov 20, 2023 19:38 ET
Merrimack Pharmaceuticals(MACK.US) Director Buys US$627.13K in Common Stocks
$Merrimack Pharmaceuticals(MACK.US)$ Director Andersen Eric purchased 50,170 shares of Common Stocks on Nov 14, 2023 at an average price of $12.5 for a total value of $627.13K. This transaction involv
moomoo NewsNov 16, 2023 17:49 ET
No Data
No Data